Biogen (BIIB) Other financing activities (2009 - 2026)
Biogen (BIIB) posted quarterly Other financing activities of -$13.3 million for Q2 2026, down 1008.33% year-over-year from $1.5 million in Q2 2025, and down 217.7% quarter-over-quarter from $11.3 million in Q1 2026.
Biogen (BIIB) Other financing activities (2009 - 2026) Analysis & Trends
Biogen's Other financing activities history runs 18 years deep, the most recent figure standing at -$13.3 million for Q2 2026.
- In Q2 2026, Other financing activities fell 1008.33% year-over-year to -$13.3 million; the TTM figure through Jun 2026 stood at $2.9 million (up 135.8% YoY), while the FY2025 annual figure was $5.0 million, up 327.27% from the prior year.
- Other financing activities for Q2 2026 stood at -$13.3 million, down from $11.3 million in the prior quarter.
- The five-year high for Other financing activities was $16.5 million in Q1 2023, with the low at -$14.8 million in Q2 2023.
- The 5-year median for Other financing activities is $1.9 million (2023), against an average of $1.4 million.
- The sharpest annual moves came in 2023 and 2026: Other financing activities soared 3950.0% in 2023, then tumbled 1008.33% in 2026.
- Biogen's Other financing activities stood at $200000.0 in 2022, then jumped by 3950.0% to $8.1 million in 2023, then sank by 45.68% to $4.4 million in 2024, then plunged by 129.55% to -$1.3 million in 2025, then tumbled by 923.08% to -$13.3 million in 2026.
- Business Quant data shows BIIB's Other financing activities at -$13.3 million in Q2 2026, $11.3 million in Q1 2026, and -$1.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.30 Mn |
| Jun 30, 2026 | -13.30 Mn |
| Mar 31, 2026 | 11.30 Mn |
| Mar 31, 2026 | 11.30 Mn |
| Dec 31, 2025 | -1.30 Mn |
| Dec 31, 2025 | -1.30 Mn |
| Sep 30, 2025 | 6.20 Mn |
| Sep 30, 2025 | 6.20 Mn |
| Jun 30, 2025 | -1.20 Mn |
| Jun 30, 2025 | -1.20 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Sep 30, 2024 | -12.60 Mn |
| Sep 30, 2024 | -12.60 Mn |
| Jun 30, 2024 | -1.30 Mn |
| Jun 30, 2024 | -1.30 Mn |
| Mar 31, 2024 | 7.30 Mn |
| Mar 31, 2024 | 7.30 Mn |